Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To understand the mechanisms leading to the poor response to this treatment, a better understanding of the PDAC immune landscape is required. The present work aims to study the immune profile in PDAC in relationship to spatial heterogeneity of the tissue microenvironment (TME) in intact tissues. Methods: Serial section and multiplex in situ analysis were performed in 42 PDAC samples to assess gene and protein expression at single-cell resolution in the: (a) tumor center (TC), (b) invasive front (IF), (c) normal parenchyma adjacent to the tumor, and (d) tumor positive and negative draining lymph nodes (LNs). Results: We observed: (a) enrichment ...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effectiv...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effectiv...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
International audiencePancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and dead...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...